The Food and Drug Administration (FDA) raised this week to the highest risk level the market withdrawal of a batch of thyroid tablets manufactured by Vitruvias Therapeutics Inc., warning that the medication could “cause serious health consequences or death.”
The federal agency reclassified the recall as Class I, the most serious category on its scale, defined as “a situation in which there is a reasonable probability that the use or exposure to a product that violates regulations will cause serious health consequences or death.”
What product is affected?
The recall pertains to the lot 504950 of Thyroid Tablets, USP 30 mg (NDC code 69680-166-00), with an expiration date of September 30, 2026.
From that lot, 3,655 units were distributed nationwide in the United States between January 31, 2025, and September 30, 2025, of which approximately 1,955 were sold.
The identified problem is that the tablets could be "super potent," meaning they may contain a concentration of thyroid hormone higher than indicated on the label, which would lead the patient to receive a dosage greater than prescribed without their knowledge.
Why is it dangerous?
Taking an excessive dose of thyroid hormone can trigger hyperthyroidism, a condition that accelerates metabolism with potentially serious consequences.
Among the documented adverse effects are heat intolerance, fatigue, nervousness, muscle weakness, hypertension, chest pain, rapid heartbeat, and heart rhythm disturbances.
The highest-risk groups are elderly patients and pregnant women, as excessive levels of thyroid hormone can lead to heart issues and maternal-fetal complications.
In more severe cases, untreated hyperthyroidism can lead to arrhythmias, atrial fibrillation, heart failure, osteoporosis, or a potentially life-threatening thyrotoxic crisis.
What should someone taking this medication do?
Vitruvias Therapeutics specified that it is "proactively notifying its wholesalers via email and phone to suspend the distribution of the product" and is coordinating the destruction of the recalled tablets.
However, the pharmaceutical company issued a clear warning: patients should not stop their treatment without first consulting their doctor, as abruptly discontinuing medication for hypothyroidism can also have health consequences.
At the time of the initial announcement in August, the company reported that no adverse health events related to this batch had been recorded.
A year with problems in thyroid medications
This recall is not an isolated case. In July 2026, Major Pharmaceuticals issued another recall of levothyroxine sodium tablets for being "subpotent," classified by the FDA as Class II, which included presentations of 25, 50, 75, 88, 112, 125, and 150 micrograms.
The difference between the two cases is significant: a subpotent medication does not adequately treat hypothyroidism, while a superpotent one can cause a hormonal overdose with immediate and potentially fatal effects, hence the Class I classification in the case of Vitruvias.
The FDA classifies recalls into three levels: Class I (high risk), Class II (moderate risk, reversible effects), and Class III (low risk). An elevation to Class I is a relatively uncommon action that indicates the agency considers the danger to be immediate and serious.
Those who believe they have tablets from lot 504950 of Vitruvias Therapeutics should consult the official FDA registry and contact their physician before making any decisions about their treatment.
Related videos:
Filed under: